These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25989920)

  • 61. The price of alcohol: a consideration of contextual factors.
    Treno AJ; Gruenewald PJ; Wood DS; Ponicki WR
    Alcohol Clin Exp Res; 2006 Oct; 30(10):1734-42. PubMed ID: 17010140
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
    Tunis SL
    Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Health Technology Assessment: managing the introduction and use of medical devices in clinical practice in Italy.
    Migliore A; Ratti M; Cerbo M; Jefferson T
    Expert Rev Med Devices; 2009 May; 6(3):251-7. PubMed ID: 19419283
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A primer on the assessment of medical technologies.
    Matuszewski KA
    Pharm Pract Manag Q; 1997 Jan; 16(4):53-65. PubMed ID: 10164160
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The changing role of economic evaluation in valuing medical technologies.
    Rotter JS; Foerster D; Bridges JF
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):711-23. PubMed ID: 23252354
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Handling uncertainty in economic evaluations of patient level data: a review of the use of Bayesian methods to inform health technology assessments.
    McCarron CE; Pullenayegum EM; Marshall DA; Goeree R; Tarride JE
    Int J Technol Assess Health Care; 2009 Oct; 25(4):546-54. PubMed ID: 19845985
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Reimbursement programs and health technology assessment for diabetes devices and supplies: a Canadian perspective.
    Cheung RY; Mui V
    J Diabetes Sci Technol; 2015 May; 9(3):706-10. PubMed ID: 25697719
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Illustrating economic evaluation of diagnostic technologies: comparing Helicobacter pylori screening strategies in prevention of gastric cancer in Canada.
    Xie F; O'Reilly D; Ferrusi IL; Blackhouse G; Bowen JM; Tarride JE; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):317-23. PubMed ID: 19394572
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review.
    Akpinar I; Jacobs P; Tran TD
    Pharmacoecon Open; 2017 Mar; 1(1):65-68. PubMed ID: 29442299
    [TBL] [Abstract][Full Text] [Related]  

  • 71. EXPLORATION AND PREFERENTIAL RANKING OF PATIENT BENEFITS OF MEDICAL DEVICES: A NEW AND GENERIC INSTRUMENT FOR HEALTH ECONOMIC ASSESSMENTS.
    Lesén E; Björholt I; Ingelgård A; Olson FJ
    Int J Technol Assess Health Care; 2017 Jan; 33(4):463-471. PubMed ID: 29065937
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Tentative guidelines for using clinical and economic evaluations revisited.
    Laupacis A; Feeny D; Detsky AS; Tugwell PX
    CMAJ; 1993 Mar; 148(6):927-9. PubMed ID: 8448707
    [No Abstract]   [Full Text] [Related]  

  • 73. Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs.
    Rothery C; Claxton K; Palmer S; Epstein D; Tarricone R; Sculpher M
    Health Econ; 2017 Feb; 26 Suppl 1():109-123. PubMed ID: 28139090
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost-effectiveness analysis: can we reduce variability in costing methods?
    Adam T; Koopmanschap MA; Evans DB
    Int J Technol Assess Health Care; 2003; 19(2):407-20. PubMed ID: 12862197
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Alternative approaches for assessing the socioeconomic benefits of medical devices: a systematic review.
    Wilkinson G; Drummond M
    Expert Rev Med Devices; 2015; 12(5):629-48. PubMed ID: 26305841
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Standardisation of costs: the Dutch Manual for Costing in economic evaluations.
    Oostenbrink JB; Koopmanschap MA; Rutten FF
    Pharmacoeconomics; 2002; 20(7):443-54. PubMed ID: 12093300
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Methods for medical device and equipment procurement and prioritization within low- and middle-income countries: findings of a systematic literature review.
    Diaconu K; Chen YF; Cummins C; Jimenez Moyao G; Manaseki-Holland S; Lilford R
    Global Health; 2017 Aug; 13(1):59. PubMed ID: 28821280
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Value-based purchasing of medical devices.
    Obremskey WT; Dail T; Jahangir AA
    Clin Orthop Relat Res; 2012 Apr; 470(4):1054-64. PubMed ID: 22033872
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pricing of medical devices under coverage uncertainty--a modelling approach.
    Girling AJ; Lilford RJ; Young TP
    Health Econ; 2012 Dec; 21(12):1502-7. PubMed ID: 22021085
    [TBL] [Abstract][Full Text] [Related]  

  • 80. FACTORS INFLUENCING REIMBURSEMENT OF MEDICAL DEVICES IN FRANCE.
    Loge P; Delalande F; Reymond MC; Germain S
    Int J Technol Assess Health Care; 2015; 31(6):399-406. PubMed ID: 26868190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.